Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases, with a strong emphasis on genetic and neuromuscular disorders. The company’s current portfolio includes approved treatments for Duchenne muscular dystrophy, alongside research programs in RNA-based medicines, gene therapy, and other genetic modalities. Sarepta Therapeutics also advances a broader pipeline for rare muscle and central nervous system diseases, reflecting its specialization in precision medicines for underserved patient populations. Its products and development efforts position the company as a notable participant in the rare-disease therapeutics market, where specialized science and targeted treatments are central to clinical and commercial activity.